AKTX
Akari Therapeutics, Plc
Set alert
- YTD
- -28.72%
- 1 year
- -71.78%
- Open
- 8.50
- Prev close
- 8.00
- Mkt cap
- 18.83M
- Vol
- 45.80K
- Avg vol
- 62.34K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.07
- High
- 8.95
- Forward P/E
- -0.29
- Beta
- 0.95
- Short ratio
- 1.92
- Inst. own
- 0.51%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 6, 2024
- 50-d avg
- 1.78
- 200-d avg
- 2.41
- 1y target
- 0.00
Key statistics
- Market cap
- 25.94M
- Enterprise value
- 35.14B
- Trailing P/E
- 0.00
- Forward P/E
- -0.29
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -2.58
- Beta
- 0.95
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -7.51M
- Total cash
- 4.18M
- Total debt
- 1.00M
- Return on equity
- 0.00%
- Shares outstanding
- 26.47M
- Short % of float
- 0.23%
- 50-day average
- 1.78
- 200-day average
- 2.41
Analyst view
Consensus: none
Next earnings
May 6, 2024
Expected May 6, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 6, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Oct 3, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| Jul 19, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Jan 6, 2023 | Sep 1, 2022 | 0.00 | — | — | — |
| Sep 27, 2022 | Jun 1, 2022 | 0.00 | -2.00 | — | — |
About Akari Therapeutics, Plc
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- akaritx.com
News
- Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why XCF Global Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Akari Therapeutics Submits PCT/US2026/45955 To Expand Its IP Portfolio
Your note
Sign in to keep a note on AKTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DICICCO WENDY FRANCES | Chief Financial Officer | Stock Award(Grant) | Apr 30, 2024 | 158,474,000 |
| PATEL SAMIR RASHMIKANT | Director | Stock Award(Grant) | Jun 27, 2024 | 3,502,890,000 |
| PRUDO-CHLEBOSZ RAYMOND M.D. | Director | Stock Award(Grant) | Dec 1, 2024 | 4,916,600,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Omnia Family Wealth, LLC | 0.33% | 87,628 | 85.88K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.13% | 33,260 | 32.59K | Sep 29, 2024 |
| Cerity Partners LLC | 0.09% | 23,643 | 23.17K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.07% | 18,069 | 17.71K | Sep 29, 2024 |
| Cresset Asset Management, LLC | 0.07% | 18,408 | 18.04K | Sep 29, 2024 |
| Cornerstone Planning Group LLC | 0.00% | 5 | 4 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 1,512 | 1.48K | Oct 30, 2024 |